ProfileGDS5678 / 1451827_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 85% 84% 82% 84% 77% 76% 73% 70% 80% 84% 82% 78% 78% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8574582
GSM967853U87-EV human glioblastoma xenograft - Control 26.3603985
GSM967854U87-EV human glioblastoma xenograft - Control 36.1726484
GSM967855U87-EV human glioblastoma xenograft - Control 46.1384682
GSM967856U87-EV human glioblastoma xenograft - Control 56.2016784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.0383277
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.9474576
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.7455673
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.3880570
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.6758180
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.1383784
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.9637182
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.4031178
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.3542978